In the midst of the COVID-19 pandemic, there were those who argued that the rapid push to develop and roll out mRNA vaccines, based on short-term clinical data, would have adverse consequences that would only be seen years later.
Some seven million have died of COVID-19, but the question remains: did the push for immunisation via new mRNA technology cost unnecessary lives, especially in those under 60 whose health vulnerabilities were limited?
A new study in JAMA Network Open provides reassurance, having assessed the potential longer-term impacts by tracking all-cause mortality across France’s vaccinated and unvaccinated populations in the 18-59-year-old cohort.
They grouped some 22.7 million people administered at least one mRNA vaccine dose from May to October 2021 and compared them with 5.9 million in the unvaccinated cohort, of whom 10.8% were later vaccinated.
×
Sign in
If this is your first visit to the new AusDoc website, reset your password
here.